United States· US:13517-135_8877f30a-f082-45f8-91f3-7de02b69f50a

Nitazoxanide

A nitazoxanide product containing nitazoxanide, registered in United States by e5 Pharma, LLC. The same ATC class is registered in 3 of our 19 countries.

ATC P01AX11

Checked against FDA National Drug Code directory (United States) on

Informational only — not a medical device.

SOURCE REGISTER · USFDA National Drug Code directory (Unite…normalisedNitazoxanideATCP01AX11REGISTER NO.US:13517-135_8877f30a…PACKS LISTED1CHECKEDSeptember 27, 2026

Where it is registered

Nitazoxanide is registered in 3 of 19 countries.

Countries holding a registration under ATC P01AX11 (nitazoxanide), each read from that country’s own register.

  • This record: United States, from FDA National Drug Code directory (United States)
  • 2 of them publish a price we can compare per daily dose

Nitazoxanide · ATC P01AX11

3 / 19 countries

  • Norwayprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FDA National Drug Code directory (United States)
Active substance
NITAZOXANIDE
Manufacturer
e5 Pharma, LLC
Country
United States (US)
ATC code
P01AX11
ATC class
Nitazoxanide
Defined daily dose
1 g, O
Reimbursed
Not published by this register
Source register
FDA National Drug Code directory (United States)
Last checked
September 27, 2026

Packs & prices · 1

  • ndc11
    13517-135-06

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

27 interactions on record for nitazoxanide.

Graded by severity as the source publishes them — 27 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Nitazoxanide · interactions on record

27 records

  • 27 moderate

Most severe, free to view

  • GlibenclamideA10BB01moderate
  • ChlorpropamideA10BB02moderate
  • TolbutamideA10BB03moderate
  • TolazamideA10BB05moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Nitazoxanide in 2 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All nitazoxanide products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ab8fbf78-8152-46da-a597-ff04f1c254be
GET /v1/drugs/ab8fbf78-8152-46da-a597-ff04f1c254be?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "route": "ORAL",
  "source": "ndc",
  "strength": "500",
  "substance": "NITAZOXANIDE",
  "productndc": "13517-135",
  "dosage_form": "TABLET",
  "dea_schedule": null,
  "strength_unit": "mg/1",
  "application_number": "ANDA214844",
  "marketing_category": "ANDA"
}

See everything about nitazoxanide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.